CheckMan Stock Market Overview
Trending Stocks
Red List
In Today's Headlines
Bitcoin exposure has powered early gains in the Porter & Company Porter Portfolio Index ETF (PCPP). The fund has grown to $23.9 million in assets less than three months after its launch, according to ETF Database data.
If you purchased or acquired stock in Bloom Energy securities between February 27, 2025 and July 8, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
The crypto-equity complex delivered a striking dispersion over the past month, with Bitcoin-adjacent names capturing wildly different shares of the same underlying rally.
NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The E.W. Scripps Company (NASDAQ: SSP) has appointed Jen Carfley, a seasoned media sales leader, as head of small and medium business growth (SMB) and direct response advertising, effective immediately.
New York, New York--(Newsfile Corp. - August 27, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Pentair plc ("Pentair" or the "Company") (NYSE: PNR) on behalf of investors that purchased or otherwise acquired Pentair securities between April 28, 2026 and July 14, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Pentair and have suffered losses, you may CLICK HERE to contact us.
Walmart's fiscal Q2 2027 report on August 20 reset how the market prices one of the safest names in retail.
BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.
DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Zeta Global's AI-led adoption, rising customer spend and Marigold synergies support growth, while channel mix and agency exposure warrant caution.